IBI-3007 / Innovent Biologics - LARVOL DELTA

The world’s first: Innovent Biologics’ TROP-2 ISAC drug is approved for clinical trials [Google translation] (bydrug.pharmcube.com) - "On December 19, the CDE official website showed that the clinical trial application for the first-in-class new drug IBI3007 injection submitted by Innovent Biologics was accepted. IBI-3007 is Innovent's TROP-2 target ISAC."

New trial • Oncology